MedTrace Logo

Pharmacokinetics of Meropenem During High-dose CRRT

NCT03507751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2023-11-28

No results posted yet for this study

Summary

Assessment of meropenem plasma concentration in critically ill patients who require CRRT (continuous renal replacement therapy). A standard dose of meropenem is administered, i.e. 1 gram every 8 hours.

Conditions

Interventions

DRUG

Meropenem

1.0 gram of meropenem given intravenously every 8 hours

DEVICE

CRRT

Continuous renal replacement therapy for three days

Sponsors & Collaborators

  • University of Warmia and Mazury in Olsztyn

    collaborator OTHER

  • Medical University of Lublin

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2018-12-31
Completion
2019-02-02
FDA Drug
Yes
FDA Device
Yes

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03507751 on ClinicalTrials.gov